-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 2~3, 2021, the Chinese Society of Clinical Oncology (CSCO) and Beijing Xisk Clinical Oncology Research Foundation jointly sponsored the "2021 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2021 China" (2021 BOC/BOA) was successfully held in Chengdu
.
.
Breaking the predicament, CDK4/6 inhibitors bring a cross-age leap for the treatment of HR+/HER2- advanced breast cancer.
Chinese data and changes in practice: MONARCH plus research provides CDK4/6 inhibitors that China’s evidence-based patients need urgently and need for their careers : Abbe expect Sealy into the health insurance as soon as possible, to benefit breast cancer patients more accurate times, "fine" endless: emphasis on standardized testing, formations, security management, so that patients benefit more in this message